
Krebs Biochemicals and Industries Share Price Today (KREBSBIO)
TODAY IN ONE LINE
KREBSBIO slipped 0.9% on light volume, in line with Nifty's -0.7% move.
With a market cap of ₹117.38 Cr., it trades at a P/E of N/A. Track live valuations, technical indicators, and peers comparison below. Check delivery conviction and recent filings to build your view.
How good is this company?
Overall performance across 5 key dimensions.
Krebs Biochemicals and Industries flags & news
Key strengths, potential risks, and recent updates.
Green Flags
- ●Quarterly OutperformanceLatest quarter Sales up 11.6% and Profit up 71.7%
- ●High Promoter HoldingPromoters hold 72.7% skin-in-the-game
- ●Virtually Debt-FreeVery low Debt-to-Equity of 0.00x
- ●Zero Pledge RiskNo recent active promoter pledging found
Red Flags
No red flags identified
Latest Krebs Biochemicals and Industries News
What changed recently?
Recent events, corporate actions, and announcements.
Krebs Biochemicals and Industries Limited valuation: P/E, P/B and sector benchmarks.
Twelve years of multiples investors have paid for Krebs Biochemicals and Industries Limited, framed against the sector median so the premium or discount is obvious at a glance.
Market-priced ratios use the latest available quote; accounting metrics use the latest reported filing. Compare values with matched peers and the company's own history.
Valuation
Profitability
Growth
Financial Health
Krebs Biochemicals and Industries Limited technical analysis: indicators, pivots and CPR.
Live RSI, MACD and moving-average signals plus today's pivot and Central Pivot Range levels for Krebs Biochemicals and Industries Limited — derived from the live tape, not yesterday's close.
Krebs Biochemicals and Industries Limited last traded at ₹54.57 with an intraday range of ₹54.54–₹55.69 — live indicator, pivot and CPR signals below.
Pivot points
Standard pivot — most widely referenced.
Pivot levels · Classic
Live: ₹54.57| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 57.63 | +3.06 | +5.60% |
| R3 | 56.48 | +1.91 | +3.49% |
| R2 | 56.08 | +1.51 | +2.77% |
| R1 | 55.33 | +0.76 | +1.39% |
| PIVOT | 54.93 | 0.36 | 0.67% |
| CURRENT | 54.57 | — | — |
| S1 | 54.18 | -0.39 | -0.72% |
| S2 | 53.78 | -0.79 | -1.44% |
| S3 | 53.03 | -1.54 | -2.83% |
| S4 | 51.88 | -2.69 | -4.94% |
KREBSBIO is trading Below CPR, indicating Bearishness
CPR is Wider, suggesting unlikely for trending moves
Day's range: ₹55.6–₹55.6
Trading Inside opening range
Krebs Biochemicals and Industries Limited financials: P&L, balance sheet, cash flow, ratios.
Reported annual and quarterly results for Krebs Biochemicals and Industries Limited — consolidated or standalone — with margins, YoY growth and key ratios inline.
Krebs Biochemicals and Industries Limited reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹117.38 Cr. and reported EPS of ₹-7.85.
Krebs Biochemicals and Industries segment analysis : revenue and profit mix.
Disclosed business segments at Krebs Biochemicals and Industries with their share of revenue and profit, switchable between consolidated and standalone reporting.
Krebs Biochemicals and Industries discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Segment-wise Financial Analysis
The Bull, Bear, and Flip case for Krebs Biochemicals and Industries Limited.
Our AI distills the core fundamental drivers supporting Krebs Biochemicals and Industries Limited, the risks that threaten it, and the quantitative conditions that could weaken the thesis.
Krebs Biochemicals and Industries Limited's investment case rests on 9 positive markers and 10 flagged concerns drawn from the latest reported filings.
What you're getting.
Strong promoter commitment at 72.74% ensures stable long-term management continuity
Diverse API portfolio spanning cholesterol, hypertension, anti-obesity, anti-inflammatory sectors
Contract manufacturing services provide revenue diversification beyond proprietary APIs
Established operational presence since 1991 with infrastructure in Visakhapatnam
Pharmaceutical sector growth trends could drive demand for API products
Key Risks.
Operating margin severely negative at -23.00% quarterly, indicating acute profitability erosion
ROCE deeply negative at -15.40%, reflecting poor capital deployment efficiency
Total equity negative at -₹1,608 Cr with debt of ₹225 Cr, raising solvency concerns
Operating cash flow negative at -₹16.76 Cr, limiting debt servicing capacity
EPS remains deeply negative at -₹7.85 with zero dividend yield
Flip Conditions.
Reassess if quarterly profit growth turns negative for two consecutive quarters. The bull case relies on compounding earnings.
Krebs Biochemicals and Industries Limited peer comparison — same-sector benchmarks.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — Krebs Biochemicals and Industries Limited is highlighted for quick read-across.
Quick Compare
Peer Comparison
| Company Name |
|---|
Krebs Biochemicals and Industries Limited chart patterns: breakouts, tops and bottoms.
Auto-detected classical chart patterns for Krebs Biochemicals and Industries Limited — Double Top/Bottom, Head & Shoulders, Triple Bottom and more — with break levels, targets and quality scores across Intraday, Daily and Weekly timeframes.
- 1Pick how to scan. Detection sets sensitivity — Daily (standard) → Weekly (big swings). History sets how far back to look.
- 2Read the summary. The tiles at the top give the current read: net bias, the strongest pattern, and the one nearest to triggering.
- 3Scan the list. Use the Actionable, Watchlist, and History tabs to browse patterns. Click a pattern card to focus it.
- 4Inspect on the chart. Focusing draws the pattern’s pivots plus its break (blue), target (amber) and invalidation lines.
- 5Filter to what matters. Use the status controls (Confirmed, Forming, Invalidated) to hide noise and find exactly what you are looking for.
Pattern history — every completed pattern and its outcome
Krebs Biochemicals and Industries Limited delivery volume — last 20 sessions of conviction.
Daily traded volume and delivery percentage for Krebs Biochemicals and Industries Limited over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in Krebs Biochemicals and Industries Limited stood at 64.1% of traded volume, against a 20-day average of 72.5%.
Krebs Biochemicals and Industries announcements: results, concalls, ratings, M&A.
Filings Krebs Biochemicals and Industries sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
Krebs Biochemicals and Industries files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 38 documents below.
Certificate under SEBI (Depositories and Participants) Regulations, 2018
Krebs Biochemicals and Industries Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018
Scheme of Arrangement
Krebs Biochemicals and Industries Limited has informed the Exchange about Scheme of Arrangement
Trading Window
Krebs Biochemicals and Industries Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider…
Copy of Newspaper Publication
Krebs Biochemicals and Industries Limited has informed the Exchange about Copy of Newspaper Publication
Krebs Biochemicals and Industries dividend history, splits and bonus issues.
Every dividend, stock split and bonus issue Krebs Biochemicals and Industries has declared, sequenced by announce and record date.
Krebs Biochemicals and Industries corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
About Krebs Biochemicals and Industries Limited: business, sector, key facts.
What Krebs Biochemicals and Industries Limited does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
Krebs Biochemicals and Industries Limited operates in the Pharmaceuticals industry under the Healthcare sector, listed as NSE: KREBSBIO, BSE: 524518.

Krebs Biochemicals & Industries Limited (KrebsBIO) is an Indian company primarily focused on the manufacturing and sale of Active Pharmaceutical Ingredients (APIs). Their core business revolves around developing and producing key components used in various pharmaceutical formulations. The company's expertise lies in utilizing biotechnological processes to create these APIs, extending their reach beyond medicine into agricultural and industrial applications.
A significant portion of KrebsBIO's product portfolio consists of APIs used in cholesterol management and steroid synthesis. Specifically, they manufacture androstenedione, lovastatin, and simvastatin, all vital components in medications aimed at lowering cholesterol levels. These products highlight their capabilities in producing complex molecules with therapeutic value.
Beyond cholesterol-focused APIs, KrebsBIO develops and offers a diverse range of other pharmaceutical ingredients. This includes amlodipine (used in anti-hypertension medications), cetirizine (an anti-histamine), orlistat (an anti-obesity drug), serratiopeptidase (an anti-inflammatory agent), telmisartan (another anti-hypertension medication), and phenylephrine (commonly found in cold and cough remedies). This broad spectrum showcases their versatility and ability to cater to various therapeutic areas.
In addition to its own product development and manufacturing, KrebsBIO actively participates in contract manufacturing services. This allows them to provide their manufacturing expertise to larger pharmaceutical and multinational companies, offering a valuable outsourcing solution for the production of APIs. This aspect diversifies their revenue streams and strengthens their position within the pharmaceutical industry.
Established in 1991 and headquartered in Visakhapatnam, India, KrebsBIO has a long history of contributing to the pharmaceutical sector. Their combination of in-house API production, biotechnological process development, and contract manufacturing capabilities positions them as a significant player in the Indian pharmaceutical landscape and a potential supplier to global markets.
Related
Peers, sector trends, screeners and strategy playbooks contextual to this stock.
- Aarey Drugs & Pharmaceuticals (AAREYDRUGS) Share PricePeer
- Aarti Drugs (AARTIDRUGS) Share PricePeer
- Aarti Pharmalabs (AARTIPHARM) Share PricePeer
- Ajanta Pharma (AJANTPHARM) Share PricePeer
- Akums Drugs and Pharmaceuticals (AKUMS) Share PricePeer
- Top Gainers TodayScreener
- EMA Crossover ScreenerScreener
- Stock Quality ScorecardScreener
- Technical DashboardScreener
- Results CalendarScreener
- FII Buying ActivityScreener
- All Technical ScreenersScreener
- All Trading StrategiesStrategy
Questions investors ask about Krebs Biochemicals and Industries Limited (KREBSBIO).
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
01What is the current share price of Krebs Biochemicals and Industries Limited (KREBSBIO)?
The current share price of Krebs Biochemicals and Industries Limited (KREBSBIO) is ₹54.57. Today, the stock has declined by ₹0.51 (0.93%), trading in a range of ₹54.54 to ₹55.69. The stock opened at ₹55.6 with a trading volume of 1,250 shares.
02What is the 52-week high and low price of Krebs Biochemicals and Industries Limited stock?
The 52-week high price of Krebs Biochemicals and Industries Limited (KREBSBIO) is ₹82.49, while the 52-week low is ₹38.33. Currently trading at ₹54.57, the stock is 36.8% away from its 52-week low and 33.8% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
03Should I buy Krebs Biochemicals and Industries Limited stock at the current price?
Whether to buy Krebs Biochemicals and Industries Limited stock at ₹54.57 depends on multiple factors. The stock is currently trading with a P/E ratio of 0.00 and P/B ratio of 0.00. Today's performance shows a loss of 0.93%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
04What is the dividend yield of Krebs Biochemicals and Industries Limited and when is the next dividend?
Krebs Biochemicals and Industries Limited offers a dividend yield of 0.00%, which means for every ₹100 invested at the current price of ₹54.57, you can expect to receive approximately ₹0.00 annually as dividends. The face value of the stock is ₹10.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
05How is Krebs Biochemicals and Industries Limited stock performing today in the market?
Krebs Biochemicals and Industries Limited stock opened at ₹55.6 and is currently trading at ₹54.57, showing a decline of ₹0.51 (0.93%). The intraday high is ₹55.69 and low is ₹54.54. The trading volume stands at 1,250 shares, indicating moderate market participation today.
06What is the P/E ratio of Krebs Biochemicals and Industries Limited and what does it indicate?
Krebs Biochemicals and Industries Limited has a Price-to-Earnings (P/E) ratio of 0.00, which means investors are willing to pay ₹0.00 for every ₹1 of earnings. With an EPS of ₹-7.85, this P/E ratio suggests the stock may be undervalued or facing growth challenges. Compare this with industry peers and historical P/E ratios for better context.
07What is the market capitalization of Krebs Biochemicals and Industries Limited?
Krebs Biochemicals and Industries Limited has a market capitalization of ₹117.38 crores, making it a small-cap company. Market cap is calculated by multiplying the current stock price (₹54.57) by the total number of outstanding shares. This metric helps investors understand the company's size, stability, and investment risk profile.
08What is the book value and P/B ratio of Krebs Biochemicals and Industries Limited?
Krebs Biochemicals and Industries Limited has a book value of ₹-75.5 per share and a Price-to-Book (P/B) ratio of 0.00. The current market price is ₹54.57, which is -172.3% above the book value. A P/B ratio below 1 may indicate undervaluation or asset quality concerns.
The data, ratios and commentary about Krebs Biochemicals and Industries Limited (KREBSBIO) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.